title: Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
abstract: BACKGROUND
  Several studies have shown that exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation myocardial infarction (STEMI). The effects of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients remain unclear. We planned to evaluate the effects of liraglutide on left ventricular function after primary percutaneous coronary intervention for STEMI.
  
  
  METHODS
  A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days). Eighty-five patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function.
  
  
  RESULTS
  At 3 months, the primary end point, a difference in change of left ventricular ejection fraction between the two groups was +4.1% (95% CI +1.1% to +6.9%) (P < .001). There was a tendency for a lower rate of no-reflow in liraglutide group that did not reach statistical significance (7% vs control group 15%, P = .20). Liraglutide could significantly improve stress hyperglycemia (P < .05). In addition, liraglutide elicited favorable changes in markers of inflammation and endothelial function.
  
  
  CONCLUSIONS
  A short 7-day course of liraglutide in STEMI patients treated with primary percutaneous coronary intervention is associated with mild improvement in left ventricular ejection fraction at 3 months.
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Wei Ren
authors.initials: WR
authors.lastname: Chen
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Shun Ying
authors.initials: SY
authors.lastname: Hu
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China. Electronic address: cyundai@vip.163.com.
authors.forename: Yun Dai
authors.initials: YD
authors.lastname: Chen
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Geng
authors.initials: G
authors.lastname: Qian
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Jun Jie
authors.initials: JJ
authors.lastname: Yang
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Zhi Feng
authors.initials: ZF
authors.lastname: Wang
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Tian
authors.affiliation: Department of Cardiology, PLA General Hospital at Beijing, China.
authors.forename: Qing Xiu
authors.initials: QX
authors.lastname: Ning
mesh_terms: D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D000069450:Liraglutide / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D011300:Preoperative Care / Q000379:methods*; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide